These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22772622)

  • 1. Cutaneous adverse drug reactions: an 8-year retrospective study on hospitalized patients in Southern China.
    Wang F; Li Y; Mo Y; Shen C; Yang L; Zhang X
    Indian J Dermatol Venereol Leprol; 2012; 78(4):488-90. PubMed ID: 22772622
    [No Abstract]   [Full Text] [Related]  

  • 2. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Choon SE; Lai NM
    Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.
    Li LF; Ma C
    Clin Exp Dermatol; 2006 Sep; 31(5):642-7. PubMed ID: 16901302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse drug reactions in a hospital-based Chinese population.
    Huang HY; Luo XQ; Chan LS; Cao ZH; Sun XF; Xu JH
    Clin Exp Dermatol; 2011 Mar; 36(2):135-41. PubMed ID: 20738322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.
    Wang F; Zhao YK; Li M; Zhu Z; Zhang X
    Cutan Ocul Toxicol; 2017 Dec; 36(4):370-376. PubMed ID: 28423957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
    Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
    J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
    Tan SK; Tay YK
    Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 10. [Stevens-Johnson syndrome and toxic epidermal necrolysis in Togo: the role of self-medication].
    Saka B; Kombaté K; Egbohou P; Mouhari-Toure A; Akakpo S; Boukari T; Tchangaï-Walla K; Pitché P
    Ann Dermatol Venereol; 2012 Jun; 139(6-7):486-7. PubMed ID: 22721483
    [No Abstract]   [Full Text] [Related]  

  • 11. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse drug reaction in patients with epilepsy after acute encephalitis.
    Mogami Y; Takahashi Y; Takayama R; Ohtani H; Ikeda H; Imai K; Shigematu H; Inoue Y
    Brain Dev; 2012 Jun; 34(6):496-503. PubMed ID: 21996031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
    Lin MS; Dai YS; Pwu RF; Chen YH; Chang NC
    Intern Med J; 2005 Mar; 35(3):188-90. PubMed ID: 15737140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug eruptions. A series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970.
    Kuokkanen K
    Acta Allergol; 1972 Dec; 27(5):407-38. PubMed ID: 4266679
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Ding WY; Lee CK; Choon SE
    Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol in dermatology.
    Tsai TF; Yeh TY
    Am J Clin Dermatol; 2010; 11(4):225-32. PubMed ID: 20509717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides.
    Kauppinen K
    Acta Derm Venereol Suppl (Stockh); 1972; 68():1-89. PubMed ID: 4403517
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
    Boccia R; Anné PR; Bourhis J; Brizel D; Daly C; Holloway N; Hymes S; Koukourakis M; Kozloff M; Turner M; Wasserman T
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):302-9. PubMed ID: 15337569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
    Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
    Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.